Business
Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease
With current HLHS treatment, only 50-60% of infants survive to adolescenceIn ELPIS I Phase 1 clinical trial, children experienced 100% transplant-free
About this update from Longeveron Inc.
[{"type":"text","content":"With current HLHS treatment, only 50-60% of infants survive to adolescenceIn ELPIS I Phase 1 clinical trial, children experienced 100% transplant-free survival up to five years of age after receiving Lomecel-B™ compared to approximate 20% mortality rate observed from historical control dataELPIS II Phase 2b clinical trial on track for completing enrollment by end of 2024Multiple nationally recognized children’s treatment centers participating in ELPIS II MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced the successful completion of an investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B™ as a potential adjunct treatment for Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric congenital heart birth defect. The investigator meeting was organized to discuss the progress to date and operational implementation of the clinical trial, inviting the principal investigator and site staff from premiere infant and children’s treatment institutions across the country. ELPIS II is on track to complete enrollment by the end of 2024. Healthcare institutions participating in the ELPIS II Phase 2 clinical trial include: Children’s Hospital of Los AngelesChildren’s Healthcare of AtlantaAnn & Robert H. Lurie Children’s Hospital of ChicagoBoston Children’s HospitalChildren’s NebraskaJohn P. and Katherine G. McGovern Medical School at University of Texas HealthPrimary Children’s Hospital, University of Utah Three additional nationally recognized pediatric cardiothoracic institutions participated in the investigator meeting as part of their preparation for participating as investigative sites in ELPIS II. “While we have made significant advances in diagnosing HLHS before a baby is born, we don’t yet know the cause, and current HLHS treatment requires infants to undergo a complex three-stage surgical reconstruction over the first 3-4 years of their life,” said Ram Kumar Subramanyan, division chief of Pediatric Cardiothoracic Surgery at Children’s Nebraska, and a Principal Investigator in ELPIS II. “Even with this comprehensive treatment, only 50% to 60% of infants survive to adolescence due to right ventricular failu...